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ripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we
set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal
fluid (CSF) AD biomarkers.
Methods: This study analyzed 593 plasma samples selected from the EuropeanMedical Information
Framework for Alzheimer’s Disease Multimodal Biomarker Discovery study, of individuals who
were cognitively healthy (n 5 242), had mild cognitive impairment (n 5 236), or had AD-type de-
mentia (n 5 115). Logistic regressions were carried out between plasma metabolites (n 5 883) and
CSF markers, magnetic resonance imaging, cognition, and clinical diagnosis.
Results: Eight metabolites were associated with amyloid b and onewith t-tau in CSF, these were pri-
mary fatty acid amides (PFAMs), lipokines, and amino acids. From these, PFAMs, glutamate, and
aspartate also associated with hippocampal volume and memory.
Discussion: PFAMs have been found increased and associated with amyloid b burden in CSF and
clinical measures.
Crown Copyright 2019 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Keywords: EMIF-AD; Alzheimer’s disease; Dementia; Amyloid; Tau; CSF; Brain volume measurements; Cognitive functionmeasurements; Metabolomics; Biomarkers1. Background
Neurodegenerative dementias are characterized by a pro-
gressive decline in cognitive function and memory perfor-
mance. Alzheimer’s disease (AD) is the most common of
the neurodegenerative dementias making it a major source
of global morbidity and mortality [1]. The World Alz-
heimer’s Report has estimated that there are more than 46
million people diagnosed with AD-type dementia and with
an aging world population this figure is expected to increase
to more than 130 million by 2050 [2]. In addition to a major
human cost, AD also poses a significant economic cost esti-
mated to increase to $1 trillion by 2018 [2].Current clinical diagnosis of AD-type dementia relies
on experienced clinicians using a battery of cognitive tests
combined with various structural and functional imaging
and cerebrospinal fluid (CSF) biomarkers to inform a
judgment-based decision, with a definitiveAD-type dementia
diagnosis only possible at postmortem. Histologic examina-
tion of brain tissue during autopsy should contain significant
evidence of extracellular amyloid b (Ab) plaques and intra-
cellular neurofibrillary tangles of hyperphosphorylated tau.
The deposition of Ab plaques has been shown to start up to
20 years before the onset of symptoms [3–5]. There have
been numerous drug candidates that have failed clinical
M. Kim et al. / Alzheimer’s & Dementia 15 (2019) 817-827 819trials in symptomatic patients, these have been unsuccessful
in producing a reversal of symptoms or a slowing of the
progression of the disease [6]. It is thought that one of the rea-
sons for the failure of these candidates is that they were not
administered during the preclinical phase of the disease.
This introduces the challenge of diagnosing people during
the preclinical phase of the disease, when they are cognitively
normal. For this to be possible, it is necessary to discover bio-
markers that can identify individuals at high risk of devel-
oping clinical AD.
Metabolomics is the study of the complete complement of
all low molecular weight metabolites (,1500 atomic mass
units, Da) [7,8]. In essence, the metabolome represents
metabolism in real time, the interaction of both genomic
and environmental exchanges. To date there have been
numerous AD metabolomic studies performed with
different metabolomic platforms (i.e., different metabolome
coverage and measurements) that aimed to identify panels
of blood biomarkers in AD [9–13]. A handful of studies
have included subjects with mild cognition problems who
went on to develop AD during follow-up to find early disease
biomarkers. These studies have uncovered metabolite panels
with potential that are awaiting validation [14,15].
Here, we aimed to identify blood metabolites associating
with CSF measures of amyloid and tau (phosphorylated and
total). The abundance of metabolites was measured using
liquid chromatography–mass spectroscopy to cover ca.
800 metabolites. The selected metabolites were thenTable 1
Sample characteristics by clinical diagnosis
Characteristics Sample size NC
Size 593 242
Gender (M/F) 281/312 50/65
Age 593 65.06 (7.93)
APOEε4 (1/2) 306/281 103/137
MMSE 590 28.80 (1.13)
Ab z score 593 0.26 (1.14)
p-tau z score 538 0.10 (0.90)
t-tau z score 538 0.06 (0.83)
MMSE 590 28.80 (1.13)
ROD z score 405 0.86 (0.52)
Attention z score 543 0.24 (1.13)
Executive z score 343 0.20 (1.10)
Language z score 572 20.14 (1.01)
Memory delayed z score 452 0.07 (1.15)
Memory immediate z score 537 20.47 (1.88)
Visuoconstruction z score 346 0.18 (1.20)
Hippocampal left 387 4411.38 (441.14)
Hippocampal right 387 3868.75 (429.20)
Hippocampal sum 387 7626.65 (837.45)
Cortical thickness in whole brain 351 2.29 (0.12)
Cortical thickness in AD regions 351 2.65 (0.17)
Taking AChEI, yes/no 210 1/40
Taking other AD medications, yes/no 210 0/41
NOTE. Results are mean (standard deviation) for continuous variables.
Abbreviations: Ab, amyloid b; AChEI, acetylcholine esterase inhibitor; AD, Alz
ment; MMSE, Mini-Mental State Examination; NC, normal cognition; ROD, rate
*c2 test.
yOne-way analysis of variance test.compared with clinical cognition measures and rate of
cognition decline, brain volumes, and diagnosis.2. Methods
2.1. Subjects
This study used plasma samples from European Medical
Information Framework for Alzheimer’s Disease (EMIF-
AD) Multimodal Biomarker Discovery study [16]. EMIF-
AD Multimodal Biomarker Discovery is a cross-cohort
study consisting of collated data from 11 European cohorts
that aims to discover novel diagnostic and prognostic
markers for AD-type dementia by performing analyses in
multiple biomarker modalities. More details on EMIF-AD
participants can be found in Section 1 of Supplementary
methods and in Bos et al. [16].
2.2. Clinical and cognitive data
In the present study, the 593 plasma samples were from
242 normal cognition (NC), 236 mild cognitive impairment
(MCI), and 115 AD participants at sampling (Table 1). Of
236 MCI participants, 83 were later diagnosed with AD-
type dementia (defined as AD converting MCI [cMCI]),
whereas 78 remained as MCI (defined as stable MCI
[sMCI]). The average follow-up length was 2.49 years.
The Mini-Mental State Examination (MMSE) score and
the rate of cognitive decline (ROD) were available for 590MCI AD Difference P value
236 115 NA
116/120 115/127 6.06! 10201*
70.44 (7.86) 69.55 (8.51) 5.61! 10204y
131/101 72/43 6.93! 10213*
25.60 (2.82) 21.07 (4.87) ,2.00! 10216y
0.77 (1.04) 1.19 (0.61) ,2.00! 10216y
0.84 (1.35) 1.28 (1.67) ,2.00! 10216y
0.90 (1.22) 1.73 (1.63) ,2.00! 10216y
25.60 (2.82) 21.07 (4.87) ,2.00! 10216y
0.22 (0.75) 21.07 (1.07) ,2.00! 10216y
20.89 (1.58) 21.77 (1.96) ,2.00! 10216y
20.81 (1.90) 22.46 (2.07) ,2.00! 10216y
20.98 (1.26) 22.13 (1.34) ,2.00! 10216y
21.26 (1.18) 22.29 (1.00) ,2.00! 10216y
21.43 (1.29) 22.24 (1.29) ,2.00! 10216y
0.13 (1.43) 21.19 (2.20) 1.41! 10208y
3294.23 (634.68) 3042.18 (463.92) ,2.00! 10216y
3413.52 (628.90) 3197.99 (496.24) ,2.00! 10216y
6707.78 (1213.79) 6242.20 (884.14) ,2.00! 10216y
2.30 (0.11) 2.28 (0.11) 5.13! 10201y
2.64 (0.16) 2.57 (0.17) 7.12! 10203y
51/66 28/24 4.90! 10207*
16/101 7/45 4.27! 10202*
heimer’s disease; APOEε4, apolipoproteinE ε4; MCI, mild cognitive impair-
of cognitive decline.
M. Kim et al. / Alzheimer’s & Dementia 15 (2019) 817-827820and 405 participants, respectively (n 5 405). Neuropsycho-
logical tests measuring five different cognitive domains
were also available: memory (delayed, n5 452 and immedi-
ate, n5 537), language (n5 572), attention (n5 543), exec-
utive functioning (n 5 434), and visuoconstruction
(n5 346). More details on how ROD and neuropsychologi-
cal test (z score) values were collected can be found in Bos
et al. [16] and in Section 2 of Supplementary methods. The
clinical design is explained in detail in Bos et al. [16,17].
Details on the amyloid and tau level measurements and
magnetic resonance imaging (MRI) and genetic analyses
can be found in Section 3 of Supplementary methods.
2.3. Metabolomics data acquisition and treatment
Relative levels of 883 plasma metabolites were measured
in fasting blood samples using three differentmass spectrom-
etrymethods. Details on the analyticalmethod and data treat-
ment can be found in Section 4 of Supplementary methods.
2.4. Statistical analyses
Before statistical analyses, baseline characteristics were
compared between the diagnostic group using the c2 test
for categorical variables and the analysis of variance for
continuous variables (Table 1). To investigate the association
of each metabolite with AD clinical variables, regression
models were applied, adjusting for age at sampling, gender,
and presence of apolipoprotein E (APOE) ε4. Adjustment
for multiple testing was applied using a Bonferroni correc-
tion P value ,7.72 ! 1025 (5.05/648), where 648 is the
number of metabolites. All associations are reported as the
change per one metabolite standard deviation.
A schematic workflow of the primary data analysis used
in this study can be found in Supplementary Fig. 1. More de-
tails on statistical analyses and the network analysis can be
found in Section 5 of Supplementary methods. More details
on statistical analyses can be found in Section 5 of
Supplementary methods. Finally, a data-driven network
analysis was performed post hoc to identify independent as-
sociations between all pairs of variables. Missing values
were imputed with the k-nearest neighbor algorithm (impute
package for R [18]) after standardizing to zero-mean and
unit-variance. To infer the partial correlation network be-
tween variables, graphical least absolute shrinkage and se-
lection operator algorithm was used [19]. The optimal
complexity network was selected with extended Bayesian
information criterion (huge package for R [20]) and visual-
ized with qgraph package for R [21]). All statistical analyses
were performed using R Statistical Software (version 3.4.1).3. Results
3.1. Demographic and cognitive comparisons
The current data set comprises 593 participants divided in
three diagnostic groups: NC (n5 242), MCI (n5 236), andAD-type dementia (n5 115). Demographic and clinical data
are presented in Table 1. There were no differences in gender
between the three diagnostic groups. The MCI and AD par-
ticipants were older when compared with NC participants.
AD participants were more frequently APOEε4 carriers
and presented higher CSFAb, p-tau, and t-tau z score levels
(all, P , .01). The z scores for Ab have inverted positive
values, this means lower CSF Ab42 and CSF Ab42/40 ratio.
All cognitive tests showed values that were lower in AD par-
ticipants when compared with MCI and NC participants (all,
P , .01). Brain volume measurements by MRI analyses
showed lower hippocampus volumes (left, right, and sum)
and average cortical thickness in AD signature regions in
AD participants (all, P , .01). No differences could be
observed between the three diagnostic groups for average
cortical thickness across the whole brain (P . .05).3.2. Association of blood metabolites with measures of
amyloid and tau in CSF
First, we aimed to identify metabolites that would asso-
ciate with AD pathologic features, namely Ab, p-tau and
t-tau z scores. For this, we built linear regression models be-
tween 648 metabolite levels and (1) Ab levels in participants
in all three diagnostic groups (NC1MCI1 AD), (2) Ab in
MCI participants, (3) p-tau in participants in all three diag-
nostic groups (NC 1 MCI 1 AD), (4) p-tau in MCI partic-
ipants, (5) t-tau in participants in all three diagnostic groups
(NC1MCI1AD), and (6) t-tau in MCI participants. Asso-
ciations in MCI participants only were performed to identify
metabolites associating with Ab and tau changes in the early
stages of AD.
After adjusting for age at sampling, gender, and APOEε4,
five metabolites were found to associate with Ab levels
across all participants at P,7.72! 1025. These fivemetab-
olites were palmitamide, oleamide, linoleamide, stearamide,
and aspartate. Palmitamide, oleamide, linoleamide, and
stearamide are primary fatty acid amides (PFAMs) and
they were increased with higher Ab levels (b 5 0.21,
b 5 0.19, b 5 0.18, and b 5 0.16) whereas aspartate was
decreased with Ab levels (b 5 20.18). The P value for
each association can be found in Table 2. In addition, a
regression model in a subset (N 5 467) investigated metab-
olite associations with CSF Ab42/40 values (Supplementary
Fig. 2). Palmitamide, oleamide, aspartate, linoleamide,
stearamide, aspartate, and glutamate associated with CSF
Ab42/40 at P ,7.72! 10
25 level.
Next, we investigated metabolites associating with Ab
levels in MCI participants. Linear regression models were
built for all 648 metabolites, eight metabolites were found
to associate with Ab at P,7.72! 1025 level. The eight me-
tabolites included thefive previousmetabolites (palmitamide,
oleamide, aspartate, linoleamide, stearamide, and aspartate)
and 9,10-DiHOME, 12,13-DiHOME, and glutamate. Palmi-
tamide (b 5 0.35), oleamide (b 5 0.35), linoleamide
(b 5 0.27), and stearamide (b 5 0.33) levels were found
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DiHOME (b 5 20.27), 12,13-DiHOME (b 5 20.28), and
glutamate (b 5 20.28) levels were found to be lower with
Ab levels (P values can be found in Table 2).
We then examined the association of each of the 648 me-
tabolites with the z score of CSF p-tau in all participants
(N 5 538) and in MCI participants (N 5 235). At P
,7.72 ! 1025 level, neither model showed metabolites
associating with p-tau. Furthermore, we investigated associ-
ation between 648 metabolites and CSF t-tau levels in all
participants (N 5 538) and in MCI participants
(N 5 235). Argininate was found to associate with CSF t-
tau levels in all participants at P ,7.72 ! 1025, its level
was found decreased with higher CSF t-tau levels
(b . 20.22). No metabolites associated with CSF t-tau in
MCI participants only. Next, we tested if these nine metab-
olites were associated to any of the drugs detected (n 5 2,
hydroquinone sulfate and salicylate), and AD medications
(n 5 2, acetyl-cholinesterase inhibitors or other AD drugs).
Regression models showed no associations between the nine
metabolites and drugs at P,7.72! 1025 (data not shown).
Overall, we investigated associations between 648 me-
tabolites and three well-established AD pathologic markers,
Ab, p-tau, and t-tau in all participants (NC 1 MCI 1 AD)
and in MCI participants only. From these models, we were
able to select nine metabolites, palmitamide, oleamide, lino-
leamide, stearamide, 9,10-DiHOME, 12,13-DiHOME,
glutamate, and aspartate, which were found to associate
with Ab levels, whereas argininate was found to associate
with t-tau levels.
Summary of the regression models between the nine me-
tabolites and clinical Ab and t-tau levels can be seen in Fig. 1
and Table 2.3.3. Association of blood panel with cognition, ROD, and
diagnosis
We next examined if any of these nine metabolites iden-
tified in the regression analyses would associate with AD
cognitive and diagnosis variables.
First, including all the diagnosis groups we investigated
the associations with MMSE scores and the ROD. Linear
regression models showed six metabolites associating with
MMSE at P ,7.72 ! 1025 level. Linoleamide
(b 5 20.98), oleamide (b 5 21.00), and palmitamide
(b 5 20.94) levels were lower whereas argininate
(b 5 0.84), aspartate (b 5 1.04), and glutamate
(b 5 0.87) levels were higher with higher MMSE scores.
Only glutamate was found to associate with ROD
(b 5 20.24) at P ,7.72 ! 1025 level (P values can be
found in Supplementary Table 1).
Then the selected nine metabolites were examined
against neuropsychological tests measuring five different
cognitive domains. Lower attention levels were found to
associate with higher levels of stearamide (b520.38), pal-
mitamide (b 5 20.43), oleamide (b 5 20.40), and
Fig. 1. (A and B) The nine selected metabolite levels vary with AD CSF marker levels in participants in all three diagnostic groups (NC, MCI, and AD). The
solid line represents a simple linear regression for themetabolite, whereas the shaded area represents the 95% confidence interval. (C) Volcano plot summarizing
results of regression models, which investigated association between 648 plasma metabolites and Ab levels in MCI participants (N5 236). Blue dots represent
metabolites passing Bonferroni correction (P , 7.72! 10205).
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metabolite associated with executive function. Lower lan-
guage levels were found to associate with higher oleamide
levels (b 5 20.25) and lower levels of glutamate
(b 5 0.2), aspartate (b 5 20.25), and argininate
(b 5 20.28) levels at P ,7.72 ! 1025 level (P values
can be found in Supplementary Table 2).
No metabolite was found to associate with delayed mem-
ory. Three metabolites associated with immediate memory,
linoleamide (b520.49), oleamide (b520.43), and palmi-
tamide (b 5 20.38). Finally with visuoconstruction scores,
no metabolites were found to associate with this function.
We were also interested on how the nine metabolites
would associate with clinical diagnosis. Three metabolites
associated with AD (vs. NC) at P,7.72! 1025 level, lower
levels of argininate (odds ratio [OR] 5 0.50), aspartate
(OR 5 0.50), and glutamate (OR 5 0.53) were found to
associate with AD. Afterward, we combined cMCI and
AD participants into one group as cMCI is often defined as
early AD. We then measured cMCI and AD against NC as
an outcome, six metabolites were found to be associated at
P,7.72! 1025 level. These six metabolites included argi-
ninate (OR 5 0.49), aspartate (OR 5 0.45), glutamate
(OR 5 0.50), linoleamide (OR 5 2.34), oleamide
(OR5 2.34), and palmitamide (OR5 2.20). We also looked
at AD conversion from MCI participants (cMCI vs. sMCI)
and found no association at P ,7.72 ! 1025 level
(Supplementary Table 2). A summary of the regression
models can be found in Supplementary Tables 1 and 2.
3.4. Associations of blood panel with brain structural
measures
In the present study, MRI data were available for 387 par-
ticipants (hippocampus volumes left, right, and sum) and
351 participants had cortical thickness measures (average
across the whole brain and in AD signature regions).
Of the nine metabolites, four metabolites were found to
associate with right hippocampus volume at P
,7.72 ! 1025 level. These included higher level of gluta-
mate (b 5 146.10) and lower levels of linoleamide
(b 5 2154.91), oleamide (b 5 2145.33), and palmitamide(b 5 2132.32). When sum of hippocampus volume was
examined as an outcome, higher level of glutamate
(b 5 273.10) and lower levels of linoleamide
(b 5 2274.93), oleamide (b 5 2268.55), and palmitamide
(b 5 2246.38) were found to associate with higher sum of
hippocampus volume (P , 7.72 ! 1025 level). Linear
regression analysis with left hippocampus volume or cortical
thickness as an outcome showed no metabolite association
(Supplementary Table 3).
Summary of all the regression models between the nine
metabolites and all AD clinical variables can be found in
Fig. 2A as a circos plot depicting 25 classes of metabolites
and nine metabolites associated with amyloid or
tau (Supplementary Fig. 3 as a heat map). Fig. 2B shows
relative levels of plasma oleamide versus amyloid levels,
Supplementary Fig. 4, relative levels of plasma oleamide
versus diagnostic groups.
3.5. Predictive models of clinical diagnosis
We built receiver operating characteristic (ROC) models
for the nine selected metabolites; Fig. 3A depicts how well
the panel can discriminate AD-type dementia from control
subjects. The resulting area under the curve (AUC) value
was 0.7811. We then examined how well other AD clinical
variables would discriminate diagnoses groups. Ab pro-
duced AUC value of 0.7814, t-tau produced AUC of
0.7815, p-tau produced AUC of 0.8541, and covariates
(known risks of age at sampling and APOEε4 status) pro-
duced AUC of 0.7035 (Fig. 3A).
Then we built ROC model (Fig. 3B) for the nine selected
metabolites for AD cMCI versus non-cMCI groups. The re-
sulting AUC value was 0.6625. This value was compared
with other AD clinical variables, Ab (AUC 5 0.6065), p-
tau (AUC 5 0.6623), t-tau (AUC 5 0.6642), and covariates
(AUC 5 0.5718).
3.6. Network analysis
To visualize the interactions in the full data set, including
metabolites and all clinical variables, a data-driven network
was computed selecting the clinical variables and
Fig. 2. (A) Circos plot to visualize the results of regression models. Orange lines represent association between AD clinical variables and nine selected me-
tabolites (P , 7.72 ! 1025). Here, we examined associations between CSF markers and 648 metabolites in 25 different classes. The circos plot shows
nine metabolites in three classes (four fatty acid amides, two fatty acids, and two amino acid metabolites) associating with at least one CSF markers. These
nine metabolites associate with other AD clinical variables, brain volumes, cognition, and diagnosis but not APOEε4. (B) Boxplot showing relative levels
of plasma oleamide according to the quartiles of amyloid levels. The size of the box represents the 25th and 75th percentiles; the central horizontal line in
the boxes represents the median; the red diamond in the boxes represents the mean. Regression models were carried out to test association between oleamide
levels between the quartiles after adjusting for age, gender, andAPOEε4 status. The asterisks represent the strength of the association after applyingmultiple test
correction. *P, .05; **P, .01; ***P, .001. Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; CSF, cerebrospinal fluid; MCI, mild cognitive
impairment; NL, normal; ROD, rate of cognitive decline.
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mine, and aspartate were strongly correlated to amyloid.
There were two additional metabolites that showed high
partial correlation to MMSE and diagnosis, these were
tryptophan, betaine, and 2-pyrrolidinone, respectively (see
Supplementary Fig. 5).Fig. 3. Receiver operator curve figures for the selected nine metabolites in (A) AD
The AUC values for the nine selected metabolites were compared with Ab (in yel
APOEε4 status (in green). Abbreviation: AUC, area under the curve.4. Discussion
At present clinical MCI and AD-type dementia diagnoses
are made based on the presentation of symptoms, cognitive
assessments, biomarker analyses, and the judgment of the
clinician. However, by the time symptoms are presentversus control subjects model and (B) AD cMCI versus non-cMCI (in red).
low), p-tau (in green), t-tau (in purple), and covariates consisting of age and
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brain. Hence the ideal plasma biomarker or panel would
give information about high amyloid levels and risk of con-
version to AD to treat at an earlier stage. In fact very few
biomarkers have been approved to this end, the positron-
emission tomography tracer florbetapir was approved by
the Food and Drug Administration in 2012 and it allows
for a measurement of amyloid burden in the brain, achieving
sensitivity of 82% to 92% and specificity of 95% [22]. CSF
measures of amyloid and tau are also widely accepted as bio-
markers of AD. A recent meta-analysis of CSF biomarkers
(12 cohorts cMCI 5 307 and sMCI 5 501), using CSF
amyloid-42, p-tau, and t-tau, conversion was predicted
with average ratios of 0.67, 1.72, and 1.76, respectively [23].
In this study, 883 structurally distinct compounds were
measured in 593 plasma samples. We found that metabolites
pertaining to three classes of compounds were associated
with amyloid or tau measures, namely four PFAMs, two
lipid hormones, and three amino acids. The panel predicted
AD-type dementia with the same AUC as amyloid
(AUC 5 0.78 for both) but lower than t-tau for this cohort
(AUC 5 0.85). For early diagnoses, in the converter group
the prediction of the panel was AUC5 0.66, higher than am-
yloid by itself (AUC5 0.60) but the same as t-tau and p-tau
in this cohort.4.1. PFAMs and AD
In this study, all four PFAMs measured in our analyses
were increased with amyloid burden. Oleamide is the most
studied and best understood PFAM. Oleamide was first iden-
tified in brains of sleep-deprived cats and mice [24] and is an
important regulatory lipid in the brain and central nervous
system. Oleamide regulates the sleep-wake cycle, memory,
locomotion, pain perception, and is anti-inflammatory, anxi-
olytic, and neuroprotective [25,26]. Administration of
oleamide protects against scopolamine-induced cognitive
impairment [27] and depression in a rat chronic stress model
[28]. Earlier metabolomic studies have shown lower serum
concentrations of oleamide in patients with AD and patients
with MCI [29,30]. Differences between our results and those
reported earlier could arise by using amyloid as the primary
outcome.
If oleamide, an endocannabinoid, is neuroprotective and
has the ability to induce sleep, it could be synthesized to
improve amyloid clearance and restore the sleep-wake cycle
disruption that is characteristic of AD [31]. Sleep depriva-
tion and its disorders are suggested to precede and predict
dementia [32–34]. During sleep the brain’s interstitial
space increases in volume by up to 60% to enable CSF to
clear neurotoxic waste into the systemic circulation [35]. It
has been now shown that positron-emission tomography am-
yloid burden increases in the hippocampus with one-night
sleep deprivation [36], this is especially interesting because
of PFAMs associated with total hippocampal volume in our
study. Moreover, it has been shown that early amyloidtoxicity can be blocked by the activation of cannabinoid re-
ceptors [37].
In addition to oleamide, we find that the plasma levels of
three other fatty acid amides, palmitamide, linoleoamide,
and stearamide, were also increased. Decreased serum pal-
mitamide in ADwas reported earlier [38]. In contrast to ole-
amide, far less is known about the biological function of
palmitamide, linoleamide, and stearamide [26]. Alterations
in the blood levels of the PFAMs have been reported for
other diseases or disease models. Lower serum oleamide
has also been found in a rat model for ischemic stroke
[39] and in premutation carriers of the fragile X mental
retardation 1 (FMR1) gene [40]. Treatment of rats with qui-
nolinic acid increased the serum levels of pentadecanamide,
palmitamide, oleamide, and stearamide [41], this is inter-
esting as quinolinic acid is produced by activated microglia
[42]. A metabolomic study of the systemic effects of
cirrhosis identified increased serum levels of oleamide
and stearamide [43].
Alterations in plasma PFAM levels in AD are likely re-
sulted from dysfunction in synthesis, degradation, or trans-
port. Little is known about PFAM transport; the major
degradative reaction for the PFAMs is their hydrolysis
into fatty acid and ammonia, a reaction catalyzed by fatty
acid amide hydrolase (FAAH) [44] and/or N-acylethanol-
amine-hydrolyzing acid amidase [45]. There are conflicting
reports regarding FAAH and AD, one report indicating that
FAAH is overexpressed [46] and another that FAAH activity
is decreased in AD [47]. An AD-related decrease in FAAH
activity could lead to increased plasma levels of the PFAMs.
In Fig. 4, the three main routes are explained, decreases in
peptidylglycine a-amidating monooxygenase expression
in cultured neuroblastoma cells yielded decreases in
PFAM levels providing evidence in vivo [48]. One report
indicated that peptidylglycine a-amidating monooxygenase
activity is lower than normal in the brain and CSF of pa-
tients with AD [49].
We also found two lipokines that were decreased in MCI
participants with higher amyloid burden in the brain.
Although there are no brain studies in which lipokines
were detected, in blood, these were negatively correlated
with both body mass index and insulin resistance in the
obese, and in another study increased after exercise
[54,55]. These findings would point out toward a
metabolic explanation that could be investigated in future
studies.
The amount of glutamate and aspartate was decreased in
plasma and associated with amyloid whereas arginine corre-
lated with t-tau. We and others have found in brain that excit-
atory neurotransmitters glutamate and aspartate were
decreased with increasing amyloid and tau burden [56],
whereas plasma arginine was not found to correlate with
CSF p-tau [57], but it has been consistently found to be
decreased in the brain of patients with AD [58,59].
A limitation of this study is that although it is a relatively
large study for metabolomics, the number of participants is
Fig. 4. PFAM biosynthesis. PFAM biosynthesis route is not clearly defined with possible routes including the direct conjugation of ammonia to a fatty acid as
catalyzed by FAAH [50], a pathway that might be unfavorable in vivo [51]. The cytochrome c catalyzed reaction of ammonia with oleoyl-Coenzyme A to pro-
duce oleamide and coenzymeAwas reported as one possible in vivo route for oleamide [52]. Peptidylglycine a-amidatingmonooxgenase–catalyzed cleavage of
N-fatty acid glycines to the PFAMs has been proven in vivo [53]. Abbreviations: FAAH, fatty acid amide hydrolase; NAAA, N-acylethanolamine-hydrolyzing
acid amidase.
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dicted AD-type dementia with an ROC AUC of 0.63 (data
not shown), which is much lower than that predicted by
the panel together with amino acids and lipokines.
In sum, our data points toward a panel of metabolites
including PFAMs, amino acids, and lipokines that could
help understand AD pathways and achieve prediction in
blood equivalent to that achieved by amyloid measures in
CSF. PFAMs are endocannabinoids that could potentially
have an anti-inflammatory and sleep-inducing role as
amyloid burden increases toxicity in the brain.Acknowledgments
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1. Systematic review: The authors reviewed the litera-
ture using PubMed and reported key publications.
Most studies were small and relatively heteroge-
neous in the metabolites identified. Most blood me-
tabolomic studies have highlighted the role of lipid
metabolites as important in Alzheimer’s disease
(AD). However, we still need to identify peripheral
early stage AD biomarkers that reflect pathology
and/or that inform on its biochemistry and potential
targets. For this, we used a comprehensive range me-
tabolomic approach to identify small molecules in
blood associating with pathology as indexed by cere-
brospinal fluid AD biomarkers.
2. Interpretation: The results show that primary fatty
acid amides (PFAMs) associated with AD pathology
and phenotype. There are two important implications
to this finding: first, the lipids in question are thought
to be synthesized in the brain; and second, they are
also thought to be natural endocannabinoids. With
the exception of oleamide, the biology behind endog-
enous PFAMs is largely unknown; it is thought that
they are synthesized to induce sedation. Neurotrans-
mitters were also flagged and these could be depleted
because of compromised synaptic signaling.
3. Future directions: Results of this study should be in-
tegrated with proteomics and genetics to find more
about mechanisms involved in blood. Future studies
should address whether PFAMs are causally related
to AD, and if it is brain or other organs with the brain
that are involved in the synthesis of PFAMs.
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